Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT00004786 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

NIH

Sponsor class

Conditions

Systemic Sclerosis
Raynaud Disease

Interventions

DRUG: iloprost

Sponsor

National Center for Research Resources (NCRR)

Collaborators

[object Object]